AMH and polycystic ovary syndrome: Therefore, a large-scale, multivariate evaluation of Anti-TPO’s impact on AMH, AFC, and FSH across age, BMI, and PCOS subgroups is critically needed to guide early fertility assessment and targeted clinical interventions.